Generic Medicine Info
Indications and Dosage
Mydriasis and cycloplegia for refraction
Adult: As 0.5, 1, or 2% soln: Instill 1 drop to each eye 30-60 min prior to procedure, may repeat after 5-15 min if necessary. Deeply pigmented eyes may require higher strength. Apply pressure over the nasolacrimal sac for 2-3 min after instillation to minimize absorption.
Child: As 0.5 or 1% soln: 3 mth to 12 yr Instill 1 drop of 1% soln to each eye 30-60 min prior to procedure; >12 yr Instill 1 drop of 0.5% soln to each eye 30-60 min prior to procedure, may repeat after 5-10 min if necessary. Apply pressure over the nasolacrimal sac for 2-3 min after instillation to minimize absorption. Observe for 45 min after instillation.

Iritis, Uveitis
Adult: As 0.5 or 1% soln: Instill 1 drop onto the affected eye(s) 6-8 hrly. Deeply pigmented eyes may require higher strength.
Child: ≥3 mth Same as adult dose.
Confirmed or suspected narrow-angle glaucoma.
Special Precautions
Patient w/ Down syndrome. Debilitated patients. Childn w/ spastic paralysis or brain damage. Pregnancy and lactation.
Adverse Reactions
Significant: Transient increase in intraocular pressure, ocular irritation and burning sensation, CNS disturbance, psychotic reactions.
Nervous: Insomnia, drowsiness, ataxia, hallucination, hyperactivity, incoherent speech, restlessness, seizure.
CV: Tachycardia.
Ophthalmologic: Accommodation disturbance, intolerance to bright light, stinging, blurring of vision, punctal stenosis.
Dermatologic: Burning sensation of the skin.
Patient Counseling Information
This drug may cause transient blurring of vision and increased sensitivity to light, if affected, do not drive or operate machinery. Remove contact lenses prior to admin and reinsert after 15 min.
Monitoring Parameters
Perform tonometric examination prior to use of drug.
Symptoms: Increased intraocular pressure, behavioural disturbances, hyperpyrexia, tachycardia, HTN, vasodilation, urinary retention, diminished GI motility, decreased salivary, sweat glands, bronchial, pharynx, and nasal secretions. Management: Supportive treatment.
Drug Interactions
May interfere w/ ocular antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
Description: Cyclopentolate is a tertiary amine antimuscarinic agent. It reversibly blocks the action of acetylcholine resulting in relaxation of innervated iris sphincter muscle producing mydriasis. Additionally, it also paralyzes the ciliary muscle of the lense producing cycloplegia.
Onset: Max: Mydriasis: Approx 30-60 min. Cycloplegia: 25-75 min.
Duration: Mydriasis: Approx 24 hr. Cycloplegia: 6-24 hr.
Absorption: May be systemically absorbed by transcorneal absorption.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Cyclopentolate, CID=2905, (accessed on Jan. 22, 2020)

Store between 20-25°C. Protect from light. Do not freeze.
MIMS Class
Mydriatic Drugs
ATC Classification
S01FA04 - cyclopentolate ; Belongs to the class of anticholinergics used as mydriatics and cycloplegics.
Anon. Cyclopentolate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 05/07/2017.

Buckingham R (ed). Cyclopentolate Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 05/07/2017.

Cyclopentolate Solution/Drops (Akorn, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 05/07/2017.

Joint Formulary Committee. Cyclopentolate Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 05/07/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Cyclopentolate Hydrochloride (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 05/07/2017.

Disclaimer: This information is independently developed by MIMS based on Cyclopentolate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in